Penumbra Inc

Penumbra, Inc. is a global healthcare company founded in 2004 and headquartered in Alameda, California. A publicly traded company listed on the New York Stock Exchange (NYSE: PEN), Penumbra reported annual revenue of approximately $1.4 billion for 2025 and employs over 4,500 people. In January 2026, Boston Scientific announced its intent to acquire Penumbra.

As an operating medical device company, Penumbra designs, develops, and manufactures therapies for challenging medical conditions. The company's product portfolio focuses on vascular conditions, particularly mechanical thrombectomy (blood clot removal) for treating ischemic stroke, pulmonary embolism, and peripheral vascular blockades. Major product lines include the Penumbra System®, Indigo® System with Lightning® Computer Assisted Vacuum Thrombectomy (CAVT™), and various neurovascular access and embolization products for treating conditions like brain aneurysms.

Penumbra's patent litigation posture is that of an operating company actively engaged in its competitive field. The company has been tracked as a plaintiff in one patent case and has no recorded defendant appearances, a profile inconsistent with that of a non-practicing entity. This plaintiff case is an assertion against a direct competitor in the medical device sector.

The company's single tracked case is Penumbra Inc v. Rapidpulse Inc, an action at the Court of Appeals for the Federal Circuit. This dispute stems from Penumbra's challenge to the validity of a RapidPulse patent for an "aspiration thrombectomy system," a technology central to Penumbra's core business. The case originated as an inter partes review proceeding before the Patent Trial and Appeal Board (PTAB), a common venue for technology companies to resolve patent disputes.